IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-24339-7.html
   My bibliography  Save this article

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

Author

Listed:
  • Donata Hoffmann

    (Friedrich-Loeffler-Institut)

  • Björn Corleis

    (Friedrich-Loeffler-Institut)

  • Susanne Rauch

    (CureVac AG)

  • Nicole Roth

    (CureVac AG)

  • Janine Mühe

    (CureVac AG)

  • Nico Joel Halwe

    (Friedrich-Loeffler-Institut)

  • Lorenz Ulrich

    (Friedrich-Loeffler-Institut)

  • Charlie Fricke

    (Friedrich-Loeffler-Institut)

  • Jacob Schön

    (Friedrich-Loeffler-Institut)

  • Anna Kraft

    (Friedrich-Loeffler-Institut)

  • Angele Breithaupt

    (Friedrich-Loeffler-Institut)

  • Kerstin Wernike

    (Friedrich-Loeffler-Institut)

  • Anna Michelitsch

    (Friedrich-Loeffler-Institut)

  • Franziska Sick

    (Friedrich-Loeffler-Institut)

  • Claudia Wylezich

    (Friedrich-Loeffler-Institut)

  • Bernd Hoffmann

    (Friedrich-Loeffler-Institut)

  • Moritz Thran

    (CureVac AG)

  • Andreas Thess

    (CureVac AG)

  • Stefan O. Mueller

    (CureVac AG)

  • Thomas C. Mettenleiter

    (Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health)

  • Benjamin Petsch

    (CureVac AG)

  • Anca Dorhoi

    (Friedrich-Loeffler-Institut)

  • Martin Beer

    (Friedrich-Loeffler-Institut)

Abstract

The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies.

Suggested Citation

  • Donata Hoffmann & Björn Corleis & Susanne Rauch & Nicole Roth & Janine Mühe & Nico Joel Halwe & Lorenz Ulrich & Charlie Fricke & Jacob Schön & Anna Kraft & Angele Breithaupt & Kerstin Wernike & Anna M, 2021. "CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2," Nature Communications, Nature, vol. 12(1), pages 1-7, December.
    • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24339-7
    DOI: 10.1038/s41467-021-24339-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-24339-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-021-24339-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24339-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.